Clinical Trials Directory

Trials / Completed

CompletedNCT05454033

A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants in China With Fine Lines Around the Mouth

Multicenter, Evaluator-blind, Randomized, No-treatment Controlled Study to Evaluate the Safety and Effectiveness of JUVÉDERM® VOLITE™ for Correction of Perioral Lines in Chinese Population

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
198 (actual)
Sponsor
AbbVie · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Facial fine lines and wrinkles are caused by skin thinning, loss of moisture, and loss of elasticity due to factors such as age, ultraviolet (UV) radiation, and environmental exposures. Today, many injectable fillers are used to treat facial aging and correct skin defects. In this study, adverse effects and effectiveness of JUVÉDERM® VOLITE™ will be assessed in correcting perioral lines (around the mouth). VOLITE is an investigational device being developed for the correction of perioral lines. In this study, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to the no-treatment control group. Adult participants seeking improvement of lines, hydration, and skin smoothness in perioral area will be enrolled. Around 198 participants will be enrolled in the study at approximately 12 sites in China. Participants in the treatment group will receive the initial injection of VOLITE; the control group will receive no treatment, but will have the opportunity to receive VOLITE after 2 months. Participants will be followed up for 12 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects, and completing questionnaires.

Conditions

Interventions

TypeNameDescription
DEVICEJUVÉDERM® VOLITE™Injection, intradermal
OTHERControlNo-treatment control

Timeline

Start date
2022-09-07
Primary completion
2024-09-03
Completion
2024-09-03
First posted
2022-07-12
Last updated
2025-12-02

Locations

11 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05454033. Inclusion in this directory is not an endorsement.